Table 2.

Effects of aerobic exercise on sleep quality in patients with lymphoma, Edmonton, Canada, 2005–2008

Baseline, mean (SD)Post-test, mean (SD)Adjusted mean change,a mean (95% CI)Adjusted between group difference in mean change,a mean (95% CI); PCohen d
Global sleep quality (0–18)
 UC4.15 (3.04)4.15 (3.19)−0.35 (−0.98 to +0.28)
 AET5.84 (3.58)4.47 (3.13)−1.00 (−1.64 to −0.35)−0.64 (−1.56 to +0.27); P = 0.167−0.19
Subjective sleep quality (0–3)
 UC0.97 (0.61)0.87 (0.62)−0.14 (−0.28 to 0.00)
 AET1.14 (0.67)0.89 (0.62)−0.20 (−0.35 to −0.06)−0.06 (−0.27 to +0.14); P = 0.556−0.09
Sleep latency (0–3)
 UC0.60 (0.85)0.68 (0.89)+0.04 (−0.16 to +0.23)
 AET0.84 (0.90)0.68 (0.89)−0.11 (−0.31 to +0.09)−0.14 (−0.43 to +0.14); P = 0.321−0.16
Sleep duration (0–3)
 UC0.63 (0.78)0.67 (0.80)−0.03 (−0.19 to +0.13)
 AET0.91 (0.76)0.72 (0.70)−0.13 (−0.29 to +0.04)−0.09 (−0.33 to +0.14); P = 0.419−0.12
Sleep efficiency (0–3)
 UC0.70 (1.01)0.65 (0.99)−0.19 (−0.41 to +0.03)
 AET1.12 (1.18)0.67 (0.91)−0.31 (−0.54 to −0.09)−0.13 (−0.44 to +0.19); P = 0.432−0.12
Sleep medication (0–3)
 UC0.37 (0.90)0.35 (0.90)−0.09 (−0.29 to +0.11)
 AET0.77 (1.15)0.67 (1.14)−0.03 (−0.23 to +0.17)+0.06 (−0.22 to +0.35); P = 0.658+0.06
Daytime dysfunction (0–3)
 UC0.88 (0.76)0.93 (0.78)+0.01 (−0.15 to +0.17)
 AET1.05 (0.85)0.84 (0.68)−0.17 (−0.33 to +0.00)−0.18 (−0.41 to +0.06); P = 0.143−0.22
Poor sleepersb (%)
 UC36.7 (48.6)41.7 (49.7)−0.0 (−12.0 to +10.4)
 AET57.9 (49.8)36.8 (48.7)−15.0 (−26.5 to −3.5)−14.2 (−30.5 to +2.1); P = 0.086−0.28
  • aAdjusted for baseline value of the outcome, type of lymphoma, disease stage, current treatment status, age, sex, and baseline exercise.

  • bBased on global sleep quality score of ≥4.3.